Indian Generic Industry Wants More As J&J Loosens Grip On Darunavir Patents
This article was originally published in The Pink Sheet Daily
J&J’s gesture to free up patents in least developed countries and Sub-Saharan Africa is greeted with mixed responses, with some calling it pragmatic while others say it is limited in scope.
You may also be interested in...
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
For Paul Stoffels, worldwide chairman, pharmaceuticals at Johnson & Johnson, innovation has been a long-time passion. Stoffels is regarded as a specialist in HIV therapies. In 1997, he left Janssen Research Foundation to become the CEO of Tibotec-Virco, which he transformed from a technology-based research company into an integrated R&D organization focused on the discovery and development of new drugs and diagnostics for HIV/AIDS and infectious diseases.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.